SciRhom

High-Level Overview

SciRhom GmbH is a biotechnology company developing first-in-class monoclonal antibodies targeting iRhom2 to treat autoimmune diseases like rheumatoid arthritis, inflammatory bowel disease (IBD), and potentially lupus nephritis. The company serves patients with life-threatening inflammatory conditions by addressing a key regulator of pro-inflammatory signaling pathways, specifically modulating the protease TACE/ADAM17 without disrupting its protective physiological roles, which could yield therapies with superior efficacy and safety.[1][2][3][4] Founded in 2016 and based in Martinsried, Germany, SciRhom has demonstrated strong growth momentum, including a €63 million ($70 million) oversubscribed Series A financing in July 2024 to advance its lead candidate SRS-878 toward clinical proof-of-concept, regulatory approval for its first clinical trial application in June 2024, and plans for first-in-human trials in Austria.[2][3][4]

Origin Story

SciRhom was founded in late 2016 in Martinsried, Germany, at the Innovation and Startup Center (IZB), initially as SciMab GmbH, to commercialize over a decade of pioneering research by Prof. Dr. Carl Blobel, a co-founder and Director of the Arthritis and Tissue Degeneration Program at Hospital for Special Surgery in New York.[1][3][4] Blobel, a rheumatology expert, identified iRhom2 as a novel therapeutic target after years of bench research on its role in regulating TACE/ADAM17 and pro-inflammatory pathways like TNF-alpha signaling.[1][2][4] Co-founders include Dr. Jens Ruhe, who brings expertise in signal transduction biology and antibody development from roles at U3 Pharma GmbH and collaborations with Prof. Axel Ullrich, biotech investor Andreas Jenne, and current CEO Dr. Jan Poth.[3][4] Early traction came from successful antibody development campaigns, securing intellectual property, and initial funding from High-Tech Gründerfonds (HTGF) starting October 2016, setting the stage for preclinical advancements and the major 2024 Series A round.[2][3]

Core Differentiators

SciRhom stands out in the autoimmune biotech space through its precision targeting of iRhom2, enabling a novel mechanism to block disease-causing inflammation while preserving TACE/ADAM17's essential functions:

• First-in-class iRhom2 antibodies: Unlike direct TACE/ADAM17 inhibitors, which face challenges due to the enzyme's physiological roles, SciRhom's approach induces immune tolerance by modulating multiple pro-inflammatory pathways (e.g., TNF-alpha) simultaneously, promising better safety and efficacy in preclinical models for rheumatoid arthritis and IBD.[1][2][4]
• Robust preclinical validation: Backed by 10+ years of research from Prof. Blobel's lab, with lead SRS-878 showing promise in inflammation models; regulatory approval for first-in-human trials accelerates path to clinic.[3][4]
• Experienced leadership and IP: Management team with deep antibody development expertise; secured proprietary IP and strong investor backing from Andera Partners, Kurma Partners, Hadean Capital, MIG Capital, Wellington Partners, and HTGF.[2][3][4]
• Strategic location and infrastructure: Hosted at IZB Martinsried, leveraging proximity to innovative biotech clusters for efficient R&D.[1][3]

Role in the Broader Tech Landscape

SciRhom rides the surging wave of autoimmune disease therapies, fueled by market forces like recent approvals of breakthroughs (e.g., anti-inflammatory biologics) and heightened investor interest amid a post-pandemic focus on immunology, with its $70 million Series A reflecting one of Germany's largest biotech rounds in 2024.[2][4] The timing is ideal: autoimmune conditions affect millions globally, yet current treatments often fall short on efficacy or safety; iRhom2's role as a "central node" in inflammation positions SciRhom to influence the ecosystem by pioneering upstream modulation of ADAM17 pathways, potentially expanding to broader immune disorders.[1][4] By translating academic research into clinic-ready assets, SciRhom strengthens Europe's biotech hub in Martinsried, fostering collaborations and attracting follow-on capital to the preclinical-to-clinical pipeline.[1][2][3]

Quick Take & Future Outlook

SciRhom is poised to enter first-in-human trials with SRS-878 in late 2024 or early 2025, targeting proof-of-concept in rheumatoid arthritis, IBD, and lupus nephritis, with the €63 million Series A funding clinical development and platform expansion.[2][3][4] Trends like AI-driven target discovery and personalized immunology will amplify its iRhom2 strategy, potentially evolving SciRhom into a multi-asset player influencing next-gen autoimmune treatments. As it advances from meticulous research to patient impact, SciRhom exemplifies how targeted innovation can redefine inflammatory disease care, fulfilling its vision of game-changing therapies.[1][3]